# Which Cannabis Compounds Have Been Tested for Gut Problems, and What the Trials Found About Symptoms Versus Inflammation

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-for-gastrointestinal-symptoms-evidence/
> **Published:** 2026-09-04T22:50:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:20-04:00
> **Clinical Summary:** Cannabis for gastrointestinal symptoms: the IBD trials improved how patients felt without changing endoscopy or inflammatory markers. Here is what that means.

---

CED Clinical Relevance #77Strong Clinical RelevanceInflammatory bowel disease is one of the most common reasons patients ask about cannabis, and the trial results here are among the most frequently misreported in the field. The distinction between feeling better and having less inflammation determines whether a patient is helped or quietly harmed.

Cannabis has been tested in inflammatory bowel disease more carefully than in most conditions, and the results are consistent and uncomfortable. Patients felt better. Their endoscopy scores and inflammatory markers did not move. That finding is real, it is repeated across trials, and it is routinely reported as though the trials showed cannabis treats inflammatory bowel disease.

Clinical Insight | CED Clinic

Across four randomized placebo-controlled trials in Crohn’s disease and ulcerative colitis, cannabis and cannabis oil improved symptom scores and quality of life while leaving endoscopic scores, C-reactive protein, and fecal calprotectin unchanged. In the 2021 Crohn’s trial published in the *Journal of Crohn’s and Colitis*, the activity index fell from 282 to 166 on cannabis oil versus 264 to 237 on placebo, while the endoscopic score moved from 10 to 7 on cannabis and 11 to 8 on placebo, a difference of nothing.

Symptom relief without measurable change in inflammation is a specific and clinically dangerous combination in inflammatory bowel disease, where ongoing inflammation causes structural damage whether or not the patient feels it.

GastrointestinalInflammatory Bowel DiseaseNausea and VomitingHyperemesisEvidence Appraisal
AudiencePatients, caregivers, and cliniciansPrimary TopicHuman trial evidence for cannabinoids in gastrointestinal disease, separated by symptom and by objective inflammationSource[Read the full source](https://doi.org/10.1093/ecco-jcc/jjab069)
Why This Matters

A patient with Crohn’s disease who feels substantially better on cannabis may reasonably conclude that the disease is improving and reduce or stop other treatment. The trial data say that assumption is not supported. Symptoms and inflammation can move independently.

The second reason is that the gut is where cannabis produces one of its most distinctive harms. Cannabinoid hyperemesis syndrome presents as a gastrointestinal complaint, is frequently worked up as one, and is made worse by the treatment patients instinctively reach for.

Inflammatory Bowel Disease: Four Trials, One Consistent and Awkward Result

Timna Naftali and colleagues in Israel have run most of the controlled work here, and the pattern across their trials does not vary.

The 2013 study in *Clinical Gastroenterology and Hepatology* randomized 21 patients with a Crohn’s Disease Activity Index above 200 who had failed steroids, immunomodulators, and anti-tumor necrosis factor agents. They smoked cannabis cigarettes containing 115 mg of THC twice daily, or placebo cigarettes made from flowers with the THC extracted, for eight weeks. The primary endpoint, complete remission defined as an index below 150, was reached by 5 of 11 on cannabis and 1 of 10 on placebo, which was not statistically significant at p = 0.43. Clinical response, defined as a fall of more than 100 points, occurred in 10 of 11 versus 4 of 10, p = 0.028. Three patients came off steroids. The trial is frequently cited as showing cannabis induces remission in Crohn’s disease. Its own authors state in the abstract that the primary endpoint was not achieved.

The 2021 trial in the *Journal of Crohn’s and Colitis* is the more informative one because it measured the gut directly. Fifty-six patients received oral cannabis oil containing 160 mg per millilitre cannabidiol and 40 mg per millilitre THC, or placebo, for eight weeks. The activity index fell from 282 to 166 on cannabis and from 264 to 237 on placebo. Quality of life rose from 74 to 91 versus 74 to 75. The Simple Endoscopic Score for Crohn’s Disease went from 10 to 7 on cannabis and 11 to 8 on placebo, p = 0.75. C-reactive protein and calprotectin were unchanged. The authors’ own conclusion is that until further studies are available, cannabis treatment in Crohn’s disease should be used only in the context of clinical trials.

In ulcerative colitis the picture repeated. A 2021 trial in *PLOS ONE* randomized 32 patients to cigarettes containing 0.5 g of dried cannabis flower with 80 mg THC or placebo for eight weeks. The Lichtiger disease activity index improved from 10.9 to 5 on cannabis versus 11 to 8 on placebo, significant between groups at p = 0.001, and quality of life improved substantially. The Mayo endoscopic score changed from 2.13 to 1.25 on cannabis and 2.15 to 1.69 on placebo, with a between-group p of 0.17. The authors wrote that the clinical benefits were not associated with significant anti-inflammatory improvement in the endoscopic score or laboratory markers.

Cannabidiol Alone Has Failed Its Primary Endpoints in Bowel Disease

The compound most heavily marketed for gut inflammation is the one with the clearest negative trials.

Naftali and colleagues randomized 20 patients with active Crohn’s disease to oral cannabidiol 10 mg twice daily or placebo for eight weeks, reported in *Digestive Diseases and Sciences* in 2017. The activity index fell from 337 to 220 on cannabidiol and from 308 to 216 on placebo. There was no difference. The paper’s title states the conclusion plainly: low-dose cannabidiol is safe but not effective. The authors note the dose may have been too low, which is a fair caveat and remains untested at higher doses in this population.

Peter Irving and colleagues ran a larger multicentre trial of a cannabidiol-rich botanical extract in ulcerative colitis over 10 weeks, published in *Inflammatory Bowel Disease* in 2018. The primary endpoint was negative: remission at end of treatment was 28 percent on extract and 26 percent on placebo. Per-protocol analyses of partial Mayo score and patient-reported outcomes favoured the extract, but a per-protocol analysis was needed because patients tolerated the extract poorly, taking on average one-third fewer capsules than the placebo group. Many of the adverse events were attributed to the THC content of the extract.

A trial where a third of the intended dose does not get taken is telling you something about tolerability, and a secondary analysis restricted to the people who managed the full dose is not the same evidence as a positive primary endpoint.

Nausea, Vomiting, and Gastroparesis: The Better-Supported Indications

The strongest gastrointestinal evidence for cannabinoids is not about inflammation at all. It is about nausea.

The 2015 *JAMA* systematic review by Whiting and colleagues found that compared with placebo or active comparators, cannabinoids produced a greater average number of patients with a complete nausea and vomiting response, 47 percent versus 20 percent, with an odds ratio of 3.82 (95 percent CI 1.55 to 9.42) across three trials. The 2026 *JAMA* review reports a pooled standardized mean difference of -0.29 (-0.39 to -0.18) for prescribed cannabinoids such as dronabinol and nabilone against placebo or active comparators in nausea and vomiting from various causes. Small, real, and the basis for the existing regulatory approvals.

Gastroparesis produced a more surprising result. Ting Zheng and colleagues at the Mayo Clinic randomized 44 patients with idiopathic or diabetic gastroparesis to pharmaceutical cannabidiol escalated to 20 mg per kilogram per day, or placebo, for four weeks, reported in *Clinical Gastroenterology and Hepatology* in 2023. Cannabidiol reduced the total Gastroparesis Cardinal Symptom Index score (p = 0.008), vomiting episodes per 24 hours (p = 0.006), and overall symptom severity (p = 0.034), and improved tolerance of liquid nutrient intake. It also slowed gastric emptying further. Symptom relief occurred despite the physiology moving in the wrong direction, which is a useful reminder that gastroparesis symptoms and gastric emptying rates are loosely coupled.

THC does the same thing. A double-blind randomized study in *Alimentary Pharmacology and Therapeutics* gave 13 healthy volunteers THC at 10 mg per square metre and found that gastric emptying of solid food slowed substantially, with 73.9 percent of the isotope still in the stomach at 120 minutes versus 45.6 percent on placebo. Anyone with pre-existing delayed emptying should know that THC is likely to slow it further.

Irritable Bowel Syndrome and the Minor Compounds: Less Than Advertised

Irritable bowel syndrome is one of the most common reasons patients try cannabis for the gut and one of the least supported by controlled data.

The most rigorous work comes from the Mayo Clinic group. In a randomized trial in *Neurogastroenterology and Motility*, 36 volunteers with diarrhea-predominant irritable bowel syndrome received dronabinol at 2.5 mg or 5 mg twice daily or placebo for two days, with transit measured by validated scintigraphy. There was no overall treatment effect on gastric, small bowel, or colonic transit. A genotype-dependent signal appeared in carriers of a particular CB1 receptor variant, which is an interesting lead and not a treatment recommendation.

For cannabigerol, beta-caryophyllene, and the other compounds routinely described as gut anti-inflammatories in product marketing, the situation is simpler. Beta-caryophyllene is a genuine selective CB2 receptor agonist, demonstrated by Gertsch and colleagues in *Proceedings of the National Academy of Sciences* in 2008 through receptor binding, human monocyte assays, and a mouse inflammation model. That is real pharmacology. It is not a human gastrointestinal trial, and no such trial has been published.

Cannabigerol has recently acquired a small number of human studies in anxiety and tolerability, none of them in gastrointestinal disease. Describing what these compounds do to a human gut is describing something that has not been measured.

Cannabinoid Hyperemesis Syndrome: The Gut Problem Cannabis Causes

No page about cannabis and the gastrointestinal tract is complete without the syndrome cannabis produces there.

Cannabinoid hyperemesis syndrome is cyclic nausea and vomiting in regular cannabis users, characteristically relieved by hot showers or baths. Joseph Habboushe and colleagues surveyed emergency department patients at a New York public hospital who reported smoking cannabis at least 20 days per month. Among 155 such patients, 32.9 percent (95 percent CI 25.5 to 40.3) met the study’s symptom criteria for the syndrome. Extrapolated nationally, the authors estimated roughly 2.75 million Americans might experience something consistent with it annually.

The clinical trap is structural. The syndrome looks like a primary gastrointestinal disorder, so it gets an endoscopy, imaging, and a negative workup. Meanwhile the patient, reasonably, increases cannabis use to control nausea, because cannabis is the thing that has controlled nausea before. That escalation worsens the cycle.

Treatment evidence is thin. A 2024 systematic review in *Academic Emergency Medicine* examined seven studies and 492 patients and found mixed evidence for topical capsaicin and possible benefit from dopamine antagonists such as haloperidol and droperidol, while calling for methodologically rigorous trials. The only intervention with consistent effect is stopping cannabis, which is the part patients find hardest to accept and which resolves the syndrome when they do.

Evidence Snapshot: Cannabinoids and the GutAnchor TrialOral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomised controlled trialDesignDouble-blind, randomised, placebo-controlled, single centre; 8 weeks of oral cannabis oil 160/40 mg per mL CBD/THCParticipants56 adults with active Crohn’s disease, mean age 34.5 yearsSymptom OutcomeCrohn’s Disease Activity Index 282 to 166 with cannabis versus 264 to 237 with placeboQuality of LifeMedian score 74 to 91 with cannabis versus 74 to 75 with placebo (p = 0.004)Objective OutcomeSimple Endoscopic Score 10 to 7 versus 11 to 8 (p = 0.75); C-reactive protein and calprotectin unchangedJournalJournal of Crohn’s and Colitis, 2021;15(11):1799-1806PMID / DOI33858011 / 10.1093/ecco-jcc/jjab069Ulcerative ColitisLichtiger index 10.9 to 5 versus 11 to 8 (between groups p = 0.001); Mayo endoscopic score between groups p = 0.17 (PMID 33571293)Negative CBD TrialsCBD 10 mg twice daily in Crohn’s: no difference from placebo (PMID 28349233). CBD-rich extract in ulcerative colitis: remission 28% versus 26% (PMID 29538683)Cannabis-Caused GI Disease32.9% of near-daily cannabis smokers surveyed in an urban emergency department met hyperemesis symptom criteria (PMID 29327809)
How Strong Is This Evidence?

By the standards of cannabis research, the inflammatory bowel disease literature is unusually good. Four randomized placebo-controlled trials, prespecified primary endpoints, objective outcome measures including endoscopy and fecal calprotectin, and authors who reported negative primary endpoints plainly rather than burying them. The sample sizes are small, ranging from 20 to 56 patients, which limits precision but does not undermine the consistency of the pattern.

The nausea evidence is moderate quality and pooled across heterogeneous trials, and it underpins existing regulatory approvals. The irritable bowel evidence is essentially a null result from one well-designed transit study. The evidence for cannabigerol and beta-caryophyllene in human gastrointestinal disease is absent, not weak.

Where This Paper Deserves Skepticism

Every one of the inflammatory bowel trials ran for eight to ten weeks. That is long enough to see a symptom effect and arguably too short to see a mucosal healing effect, which in inflammatory bowel disease trials of conventional agents is usually assessed at least at week 12 and often later. The absence of endoscopic change may reflect duration as well as biology.

Blinding is again a problem. The two smoked-cannabis trials used THC-extracted placebo cigarettes, and participants receiving 80 to 115 mg of THC daily would have had little difficulty identifying their arm. Subjective activity indices such as the Crohn’s Disease Activity Index include patient-reported items and are vulnerable to that.

The gastroparesis trial ran for four weeks in 44 patients with a cannabidiol dose used in epilepsy, far above anything available over the counter. Its results should not be read as support for consumer cannabidiol products in gastrointestinal symptoms.

What This Paper Does Not Show

None of these trials show that cannabis or cannabidiol reduces intestinal inflammation in humans. Endoscopic scores, C-reactive protein, and fecal calprotectin were measured directly and did not change. That is a measured negative result, not an untested question.

No trial shows that cannabis prevents flares, reduces surgery or hospitalization, permits reduction of conventional therapy safely, or alters the long-term course of Crohn’s disease or ulcerative colitis. No published human trial tests cannabigerol or beta-caryophyllene for any gastrointestinal condition.

How This Fits With the Broader Clinical Conversation

The gap between symptom scores and objective inflammation is one of the central problems in inflammatory bowel disease care generally, and it long predates cannabis. Patients with quiescent symptoms can have active inflammation, and patients with severe symptoms can have a healed mucosa. Modern treatment targets are defined by objective measures for exactly that reason.

Cannabis enters that context as a drug that reliably moves the subjective side and, on the evidence available, does not move the objective side. That makes it a plausible adjunct for symptom burden in a patient whose inflammation is being controlled by something else, and a poor candidate for anything resembling monotherapy.

It also raises a question the trials cannot answer. If a patient feels dramatically better and their calprotectin has not moved, has their quality of life improved or has their early warning system been muted? That is not a hypothetical concern in a disease where silent inflammation causes strictures and surgery.

Dr. Caplan’s Take

This is the page where I most often disagree with how my own field talks. The 2013 Crohn’s trial is quoted everywhere as proof that cannabis induces remission, and the authors state in their own abstract that the primary endpoint was not achieved. That is not a subtle misreading. It is the opposite of what the paper says.

What I tell patients with inflammatory bowel disease is straightforward. Cannabis may genuinely make you feel better, and the trials support that. It has not been shown to reduce the inflammation that is doing the damage, and your gastroenterologist should keep measuring that independently of how you feel. If your symptom scores improve and your calprotectin does not, we have improved your day and not your disease.

And I ask about hot showers. Anyone with months of cyclic vomiting, a clean workup, and a daily cannabis habit gets that question, because the answer changes the entire diagnosis and nobody else in the chain has asked it.

Clinical Bottom Line

For inflammatory bowel disease, cannabis improves symptoms and quality of life without measurable effect on endoscopic scores or inflammatory markers across four randomized trials, and low-dose cannabidiol alone has failed its primary endpoints twice. For nausea and vomiting, cannabinoids have modest pooled benefit and existing regulatory approval. For irritable bowel syndrome, a well-designed transit study found nothing. Anyone using cannabis for gut symptoms should keep objective inflammation monitored separately, and anyone with cyclic vomiting relieved by hot showers should be evaluated for cannabinoid hyperemesis syndrome.

What a Careful Reader Should Take Away

The finding to carry forward is the dissociation between symptoms and inflammation, because it decides how cannabis should be positioned: possibly useful alongside disease-directed therapy, unsupported as a replacement for it. The finding not to carry forward is any claim that these trials demonstrated an anti-inflammatory effect in the human gut. They measured for one and did not find it.

Evidence Interpretation Guide

Table of Contents

- [How to read a trial that improves symptoms and moves no objective marker](#How_to_read_a_trial_that_improves_symptoms_and_moves_no_objective_marker)
- [Cannabis and the Gut, Seen From Eight Angles](#Cannabis_and_the_Gut_Seen_From_Eight_Angles)[Feeling better is worth something, and it is not the same as healing](#Feeling_better_is_worth_something_and_it_is_not_the_same_as_healing)
- [Position it as adjunctive, and keep objective targets independent](#Position_it_as_adjunctive_and_keep_objective_targets_independent)
- [Blinding and duration cut both ways](#Blinding_and_duration_cut_both_ways)
- [How the 2013 trial gets misquoted](#How_the_2013_trial_gets_misquoted)
- [Cannabidiol alone has now failed twice](#Cannabidiol_alone_has_now_failed_twice)
- [What to do with delayed gastric emptying](#What_to_do_with_delayed_gastric_emptying)
- [The trial this field needs](#The_trial_this_field_needs)
- [Product marketing has outrun the evidence entirely](#Product_marketing_has_outrun_the_evidence_entirely)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to read a trial that improves symptoms and moves no objective marker

The Research QuestionDo cannabis and specific cannabinoids improve gastrointestinal disease activity, and does any measured improvement extend to endoscopic and laboratory markers of inflammation?The Patient QuestionMy gut symptoms are better on cannabis. Does that mean my disease is under control?The Bottom LineAcross four randomized trials in Crohn’s disease and ulcerative colitis, symptom and quality of life scores improved while endoscopy, C-reactive protein, and calprotectin did not. Feeling better and being better are separate measurements here.
CED Perspective Lens

## Cannabis and the Gut, Seen From Eight Angles

A small but unusually well-designed trial literature, read for what it measured rather than what it is quoted as showing.

Lens OverviewRandomized trials in inflammatory bowel disease consistently show symptom and quality of life improvement with cannabis alongside unchanged endoscopic scores and inflammatory markers, while cannabidiol alone has failed its primary endpoints in both Crohn’s disease and ulcerative colitis.

#### Feeling better is worth something, and it is not the same as healing

In the trials, people with Crohn’s disease and ulcerative colitis reported meaningfully less symptom burden and better quality of life on cannabis. That is a genuine result and it matters, particularly in diseases that are exhausting to live with.

In the same trials, the camera and the blood tests showed no improvement. If you feel better on cannabis, keep taking your prescribed treatment and keep your monitoring appointments, because the inflammation is being measured by something other than how you feel.

Lens takeawaySymptom relief is real. It is not evidence your disease is quieter, so keep the objective monitoring.

#### Position it as adjunctive, and keep objective targets independent

The reasonable clinical use of cannabis in inflammatory bowel disease is as an adjunct for symptom burden in a patient whose inflammation is controlled by disease-directed therapy, with calprotectin and endoscopic assessment continuing on the normal schedule.

The risk to manage is treat-to-target drift. A patient with dramatic symptom improvement may push to reduce a biologic or immunomodulator. The trial data provide no support for that, and the dissociation between symptoms and inflammation is the reason objective targets exist.

Lens takeawayAdjunct for symptoms, never a substitute for disease-directed therapy, with objective monitoring unchanged.

#### Blinding and duration cut both ways

Patients smoking 80 to 115 mg of THC daily against extracted-flower placebo knew which arm they were in, and the activity indices include patient-reported components. Some of the symptom benefit is plausibly expectancy.

In the other direction, eight weeks is short for mucosal healing. The absence of endoscopic change is a real negative result at eight weeks and a weaker one about what a year of treatment might do.

Lens takeawayThe symptom effect may be inflated by unblinding; the endoscopic null may be limited by duration.

#### How the 2013 trial gets misquoted

The 2013 Crohn’s study is the single most miscited paper in this area. Its prespecified primary endpoint was complete remission, reached by 5 of 11 versus 1 of 10 at p = 0.43. That is a negative primary endpoint in a 21-person trial.

The significant result was a secondary clinical response endpoint. Reporting the paper as demonstrating remission induction reverses its own stated conclusion, and that error has propagated through review articles and marketing material for over a decade.

Lens takeawayCheck the primary endpoint before repeating a claim about this literature.

#### Cannabidiol alone has now failed twice

Low-dose oral cannabidiol at 10 mg twice daily was indistinguishable from placebo in active Crohn’s disease. A cannabidiol-rich botanical extract missed its primary endpoint in ulcerative colitis, with remission rates of 28 percent versus 26 percent.

The Crohn’s authors suggested the dose may have been too low and that synergy with other cannabinoids might be required. Both are plausible hypotheses, and neither has been tested in an adequately powered trial.

Lens takeawayThe compound marketed hardest for gut inflammation has the clearest negative trials.

#### What to do with delayed gastric emptying

Both THC and high-dose cannabidiol slow gastric emptying in controlled studies. In gastroparesis, cannabidiol improved symptoms while slowing emptying further, so symptom response does not indicate physiological improvement.

For anyone with known delayed emptying, that means expecting more variable absorption of oral medication and oral cannabis products, and treating a symptomatic response as symptomatic rather than corrective.

Lens takeawayExpect slower emptying, more erratic oral absorption, and symptom relief that does not reflect motility.

#### The trial this field needs

A twelve-month randomized trial with mucosal healing and calprotectin as primary endpoints, using a characterized oral preparation at a defined dose, would settle whether the eight-week endoscopic null reflects biology or duration.

A dose-ranging study of cannabidiol well above 20 mg daily in Crohn’s disease would test the explanation its own investigators offered for the negative result.

Lens takeawayLonger duration, objective primary endpoints, and a real dose range would answer the open questions.

#### Product marketing has outrun the evidence entirely

Cannabigerol and beta-caryophyllene are sold with explicit gut anti-inflammatory claims. Neither has a published human gastrointestinal trial. Beta-caryophyllene’s CB2 agonism is well established in receptor assays and mouse models, which is a mechanism, not an outcome.

Meanwhile the compound with real randomized trials in the relevant diseases produced negative primary endpoints. The ordering of marketing confidence and evidence strength is close to inverted.

Lens takeawayClaims about minor compounds in the gut currently rest on mechanism and mouse data alone.
Related Reading at CED ClinicContinue exploring the evidence[Relief Is Not the Same as Slowing a Disease](https://cedclinic.com/cannabis-and-disease-progression-symptom-relief/)

The central distinction on this page, traced across the conditions where cannabis has been tested.

[See the distinction explained](https://cedclinic.com/cannabis-and-disease-progression-symptom-relief/)[Emergency Department Visits for Cannabis Hyperemesis Syndrome Surge in Young Adults](https://cedclinic.com/cannabis-hyperemesis-syndrome-diagnosis-ed-visits-surge/)

Surveillance data on the gastrointestinal syndrome cannabis itself produces, and how it is diagnosed.

[Read the hyperemesis data](https://cedclinic.com/cannabis-hyperemesis-syndrome-diagnosis-ed-visits-surge/)[CBG, CBN, CBC, and THCV: Which Cannabinoid Claims Come From Human Studies](https://cedclinic.com/minor-cannabinoids-human-evidence/)

The evidence tier for the minor cannabinoids marketed for gut inflammation, sorted by what has been tested in people.

[Check the human evidence](https://cedclinic.com/minor-cannabinoids-human-evidence/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Does cannabis treat Crohn’s disease?

Randomized trials show symptom improvement without measurable change in inflammation. In a 2021 trial of 56 patients, the Crohn’s Disease Activity Index fell from 282 to 166 on cannabis oil versus 264 to 237 on placebo, while the endoscopic score and both C-reactive protein and calprotectin were unchanged. The trial authors concluded that cannabis in Crohn’s disease should be used only within clinical trials until further evidence exists.

Did the 2013 cannabis trial show remission in Crohn’s disease?

No. That trial randomized 21 refractory patients and its primary endpoint was complete remission, achieved by 5 of 11 on cannabis and 1 of 10 on placebo, which was not statistically significant at p = 0.43. The significant finding was a secondary clinical response endpoint, 10 of 11 versus 4 of 10. The paper is widely cited as demonstrating remission, which reverses its own stated conclusion.

Does CBD help ulcerative colitis?

The controlled evidence is negative on primary endpoints. A 10-week multicentre trial of a cannabidiol-rich botanical extract found remission rates of 28 percent versus 26 percent on placebo. Patients tolerated the extract poorly, taking about one-third fewer capsules than the placebo group, with many adverse events attributed to its THC content. Some per-protocol secondary outcomes favoured the extract, which is weaker evidence than a positive primary endpoint.

Does cannabis reduce gut inflammation?

Not by any measure the trials used. Across randomized studies in Crohn’s disease and ulcerative colitis, endoscopic scores, C-reactive protein, and fecal calprotectin were assessed directly and did not improve relative to placebo. This is a measured negative result rather than an untested question, and it is the single most important finding for anyone deciding how to position cannabis in inflammatory bowel disease.

Does cannabis help irritable bowel syndrome?

Controlled evidence is minimal and largely negative. A randomized trial of 36 patients with diarrhea-predominant irritable bowel syndrome found that dronabinol at 2.5 or 5 mg twice daily had no overall effect on gastric, small bowel, or colonic transit measured by scintigraphy. A genotype-dependent signal appeared in carriers of a particular CB1 receptor variant, which is a research lead rather than a treatment recommendation.

Do cannabinoids help nausea and vomiting?

This is the best-supported gastrointestinal indication. A 2015 systematic review found complete nausea and vomiting response in 47 percent on cannabinoids versus 20 percent on comparators, with an odds ratio of 3.82. A 2026 review reports a pooled standardized mean difference of -0.29 for prescribed cannabinoids such as dronabinol and nabilone. The effect is modest and underpins existing regulatory approvals for chemotherapy-related nausea.

What is cannabinoid hyperemesis syndrome?

It is cyclic nausea and vomiting in regular cannabis users, characteristically relieved by hot showers or baths. Among emergency department patients smoking cannabis at least 20 days per month, 32.9 percent met symptom criteria in one survey. It is commonly mistaken for a primary gastrointestinal disorder, and patients often increase cannabis to control the nausea, which worsens the cycle. Stopping cannabis is the only consistently effective treatment.

Do CBG or beta-caryophyllene help gut inflammation?

No published human gastrointestinal trial exists for either compound. Beta-caryophyllene is a genuine selective CB2 receptor agonist demonstrated in receptor binding studies, human monocyte assays, and a mouse inflammation model, which establishes a mechanism rather than a clinical outcome. Cannabigerol has a small number of human studies in anxiety and tolerability, none in gastrointestinal disease. Product claims here rest on preclinical data alone.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).